Ben Zimmer
CEO - Alyvant; President - Roivant Health

Ben serves as Alyvant’s CEO and the President of Roivant Health, where he leads the launch of new companies to improve the drug development and healthcare delivery processes.  Ben previously led teams to accelerate clinical trial enrollment at Roivant’s biotechnology companies.  Prior to Roivant, he worked as a management consultant at McKinsey & Company and on several start-ups outside the biopharmaceutical sector.  He received his A.B. from Harvard and his J.D. from Yale.

Gillian Cannon

Gillian has worked in the pharmaceutical industry for over 30 years in senior US, European and Global leadership positions at multiple pharmaceutical companies including Merck, Otsuka, and UCB.  She has expertise across a range of disciplines including Market Access, Sales, Marketing, Business Development and Strategic Planning.

Mitchell Mittman
Chief Technology Officer

Mitchell has over 35 years of experience in software, both in development and management. He has created platforms for major investment banks and corporations during his tenures at Goldman Sachs,  Bank of America and Amazon. As a founding partner of TraderTools, Mitchell supplied trading systems and real-time data management tools  to large companies, including Credit Suisse, Credit Lyonnais, Dresdner, Societe Generale and WestLB.

Nik Khetarpal
Chief Financial Officer

Nik has over 12 years of experience investing in biotech and pharma companies.  For nearly a decade, Nik was a buy-side analyst covering the therapeutics sector at multi-billion dollar hedge funds including Citadel and Soros.  Prior to joining Alyvant, Nik was Managing Director at Tourbillon Capital where he managed a $1B healthcare portfolio dedicated to biotech and pharma investments.

Bob Elliott
Chief Business Officer

Bob has 20 years of experience driving success in high performing organizations across disciplines. For the majority of his career, Bob led much of the development of new systematic alpha investment strategies at Bridgewater Associates, the world’s largest hedge fund.  While at Bridgewater, Bob proved his interdisciplinary abilities by stretching into building strategic partnerships with institutional investors and policymakers, and managing a range of business disciplines including security and technology.

Maria Goutsou
Senior Vice President of Strategy & Analytics

Maria has worked in the pharmaceutical industry for more than 20 years in various commercial appointments. Before Alyvant, she was VP of Commercial Strategy and Analytics in UCB, VP Strategy and Business Analytics at Otsuka Pharmaceuticals, and Executive Director at Merck & Co. She has also held  leadership roles in Brand Management and M&A Integration Teams.


Shannon Lindsley
Head of Sales

Shannon has over 15 years of broad-based biotech, med tech and pharmaceutical experience leading commercial strategy and building high-performing sales organizations.  She has experience in a variety of leadership roles including commercial operations, payer partnerships, marketing and sales in large organizations as well as early stage medical technology start-ups.

Theodore Dasher
Vice President of Innovative Deployment

Theo is an experienced innovator with a demonstrated history of work in the pharmaceutical, finance, and computer software industries.  Theo has a BS and MS in Statistics from Carnegie Mellon.

Mark Solomon
General Counsel & Chief Privacy Officer

Mark serves as Alyvant’s General Counsel and Chief Privacy Officer. He has over 16 years of legal experience as both in-house and external counsel, having most recently served as the general counsel of several data-driven technology startups. Mark holds a B.A. in English from Columbia College and a J.D. from Columbia Law School.